在乳腺癌幸存者的阿片类药物使用和不良健康影响
Reina Haque1,2, Lie Hong Chen1, Jiaxiao Shi1
1Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA 91101, United States.
The oncologist
|October 14, 2024
概括
阿片类药物使用很常见,并且与乳腺癌幸存者的治疗后跌倒,骨折,肺部和心血管问题的风险增加有关. 仔细监测和替代性疼痛管理至关重要.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 关于阿片类药物使用对乳腺癌幸存者的治疗后不良影响的有限数据.
- 之前的研究没有使用这个人群的年龄相匹配的对照组.
研究的目的:
- 为了检查乳腺癌幸存者的阿片类药物使用模式.
- 评估与阿片类药物使用相关的跌倒,骨折,肺部问题和心血管事件的风险.
主要方法:
- 长度队列研究涉及33,989名乳腺癌幸存者和157,609名没有癌症的年龄相匹配的女性.
- 分析不良事件率和多变量危险比率,以确定阿片类药物使用与不良健康结果之间的关联.
主要成果:
- 与对照组相比,乳腺癌幸存者使用阿片类药物的比例较高 (60%与48%),持续时间较长,阿片类药物处方较强.
- 乳腺癌幸存者的阿片类药物使用与与非阿片类药物使用者相比,在匹配的队列中,跌倒风险高12%,骨折风险高56%.
- 在乳腺癌幸存者组中,阿片类药物使用显著增加了跌倒 (HR=1.74),骨折 (HR=2.10),肺部问题 (HR=1.53) 和心血管事件 (HR=1.70) 的风险.
结论:
- 包括高剂量的阿片类药物在内的阿片类药物使用在积极治疗后在乳腺癌幸存者中普遍存在.
- 在这个人群中,阿片类药物的使用与跌倒,骨折,肺部问题和心血管事件的风险增加有关.
- 强调需要对阿片类药物使用进行警监测,并对乳腺癌幸存者的替代疼痛管理策略进行调查.
相关概念视频
Opioid Analgesics: Synthetic and Semisynthetic Opioids
237
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
237
Opioid Analgesics: Morphine and Other Natural Cogeners
188
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
188
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
203
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
203
Analgesia and Pain Management
540
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
540
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Opioid Receptors: Overview
555
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
555


